

# Performance of the Tuberculin Skin Test and Interferon- $\gamma$ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches

Delia Goletti, Alessandro Sanduzzi, and Giovanni Delogu

**ABSTRACT.** An association between biologic agents and reactivation of active disease from latent tuberculosis infection (LTBI) has been established. Screening for LTBI is, therefore, now recommended for candidates for biologic drugs. The tuberculin skin test (TST) and interferon- $\gamma$  release assays (IGRA) are the available commercial tests for detecting LTBI. We discuss their accuracy in immune-competent subjects and patients with autoimmune diseases, as well as potential new approaches to immune diagnosis. IGRA seem to be more accurate than TST in bacillus Calmette-Guérin vaccinated subjects and patients with autoimmune diseases. However, longitudinal studies are needed to estimate the risk of progression to TB after IGRA-based and/or TST-based diagnosis of LTBI in these vulnerable patients. New tests are needed to identify those patients with LTBI who will develop active TB and need prophylaxis. (J Rheumatol Suppl. 2014 May; 91:24–31; doi:10.3899/jrheum.140099)

*Key Indexing Terms:*

BIOLOGIC AGENTS	ANTI-TUMOR NECROSIS FACTOR THERAPY	TST
TUBERCULOSIS	LATENT TUBERCULOSIS	IGRA

Using a clinically pragmatic approach, one might define latent tuberculosis infection (LTBI) by the presence of a specific immune response detected by the tuberculin skin test (TST) or an interferon- $\gamma$  release assay (IGRA), in the absence of active tuberculosis (TB). However, this response is not *per se* indicative of the risk of developing future active TB<sup>1,2</sup>. LTBI can be reactivated following a waning of the immune response, as in human immunodeficiency virus (HIV) infection, malnutrition, or after the use of immune-suppressant drugs in the context of transplantation or autoimmune diseases. In particular, it has been shown that treating autoimmune diseases with biologic drugs, such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) inhibitors, increases the risk of TB development by 1.6- to 25-fold, depending on the clinical settings and the TNF antagonist used<sup>3,4,5</sup>. Here we discuss available commercial tests for

measuring LTBI, their accuracy in immune-competent subjects and patients with autoimmune diseases, and potential new approaches to TB immune diagnosis.

## Tests for Measuring Latent TB Infection

There are 2 types of tests for measuring LTBI, the TST and IGRA, both of which have advantages and disadvantages in particular circumstances (Table 1).

*Tuberculin skin test.* The TST has been available for the last 100 years. It consists of the intradermal injection of purified protein derivative (PPD), which induces a delayed-type hypersensitivity response. Tuberculin PPD is a crude mixture of antigens in which heat shock proteins predominate<sup>6</sup>, many of which are shared by *Mycobacterium tuberculosis* (Mtb), *M. bovis*, *M. bovis* Bacillus Calmette Guérin (BCG), and several species of environmental mycobacteria. TST reactions are measured in mm of diameter of induration, 48–72 h after injection of the antigen.

From a histological point of view, the classic model of cellular infiltration during a delayed-type hypersensitivity response suggests that cell migration is biphasic, comprising an initial nonspecific infiltration (neutrophils) that also occurs in nonsensitized subjects, and a second specific peak (mainly CD4 T cells)<sup>7,8,9,10,11</sup>. The mechanism of this cellular infiltration is not completely clear, but it is likely that early after the injection, proinflammatory cytokines such as interferon- $\gamma$  (IFN- $\gamma$ ), TNF- $\alpha$ , and TNF- $\beta$  stimulate expression of adhesion molecules (e.g., E-selectin) on the endothelium and increase the permeability of the local blood

---

From the Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome; Respiratory Division, Department of Clinical and Surgery Medicine, University Federico II, Naples; and Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.

D. Goletti, MD, PhD, Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases; A. Sanduzzi, MD, Respiratory Division, Department of Clinical and Surgery Medicine, University Federico II; G. Delogu, PhD, Istituto di Microbiologia, Università Cattolica del Sacro Cuore.

Address correspondence to Dr. Goletti, Istituto Nazionale per le Malattie Infettive "L. Spallanzani," Via Portuense 292, Rome 00149, Italy; E-mail: delia.goletti@inmi.it

Table 1. Characteristics of immune diagnostic tests for tuberculosis.

Test Characteristics	TST	QFT-GIT	T-SPOT TB
Internal control	No	Yes	Yes
Mtb-specific antigen	No	Yes	Yes
Test substrate	skin	Whole blood	PBMC
Time required for results, h	72	16–20	16–20
Cells involved	Neutrophils, CD4, CD8 that transmigrate out of capillaries into the skin. Role of Treg [CD4+CD25 <sup>high</sup> FoxP3+] (10–12)	CD4 T cells <i>in vitro</i> with effector memory and central memory phenotype	CD4 T cells <i>in vitro</i> with effector memory and central memory phenotype
Cytokines involved	IFN- $\gamma$ , TNF- $\alpha$ , TNF- $\beta$ (10, 11)	IFN- $\gamma$	IFN- $\gamma$
Overall sensitivity for TB infection			
HIV-uninfected	77% (32)	70–80% (32)	80–91% (32)
Overall specificity for TB infection	59%/97% (32, 33)	96% (32)	93% (32)
Overall specificity for active TB	—	79% (33)	59% (33)
Criteria for conversion established by evidence	Yes	No	No
Cutoff established depending on age, immune suppression, BCG vaccination status	Yes	No	No
Ability to detect those at high risk of developing active TB	Weak (32, 37)	Weak (32, 37, 38)	Weak (32, 37, 38)

Values in parentheses are reference numbers. TB: tuberculosis; BCG: bacillus Calmette Guerin; IFN: interferon; TNF: tumor necrosis factor; TST: tuberculin skin test; QFT-GIT: QuantiFERON TB Gold in tube; PBMC: peripheral blood mononuclear cells; HIV: human immunodeficiency virus.

vessels. Circulating CD4+CD25+FoxP3+ Treg cells influence the area of the TST induration<sup>12</sup>. Cutaneous CD4 T cells accumulating after PPD stimulation have a predominant CD45RO memory phenotype<sup>12</sup>.

It is widely accepted that an induration > 5 mm is a positive reaction. Different cutoff sizes that allow for estimating the risk of developing TB, based on factors such as age, BCG-vaccination, and immune suppression diseases are also considered.

Although broadly used, TST has limitations. Sensitivity may be reduced by malnutrition, severe active TB disease, and immunodeficiency states, such as that related to HIV infection<sup>13</sup>. Decreased specificity is associated with exposure to nontuberculous mycobacteria and BCG-vaccination, although after 10 years or more, the effect of BCG-vaccination on TST reactions is limited if the vaccination was given in infancy<sup>14</sup>. Moreover, a TST necessitates 2 healthcare visits, one for the PPD injection and the other to measure the induration, leading to a loss of reading in around 10% of the cases<sup>15</sup>. Cutoff points have been defined to identify when preventive therapy is indicated for different age and risk groups<sup>16</sup>. Definitions of conversion and boosting have also been established; conversion is defined as an induration over 10 mm with an increase of at least 6 mm over the previous result<sup>17</sup>. The positive predictive value for TB development is low when considering high-prevalence and low- and middle-income settings<sup>18</sup>, but increases in those with immunodeficiency<sup>19,20,21</sup>.

*IFN- $\gamma$  release assays.* IGRA have been available only for the past decade. Two licensed IGRA exist: QuantiFERON TB Gold in tubes (Cellestis, a QIAGEN Company; QFT-GIT)

and T-SPOT.TB (Oxford Immunotec). Both tests measure *in vitro* IFN- $\gamma$  production by a whole blood ELISA<sup>22</sup> or an enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells<sup>23,24</sup> (Table 1). The IFN- $\gamma$  is produced by circulating T cells after 16–20 h stimulation in response to Mtb-specific antigens. The genes encoding these antigens are found in the regions of difference (RD), either RD1 (CFP-10 and ESAT-6) or RD11 (TB7.7), of the Mtb genome, which are deleted from the genome of *M. bovis* BCG and are not present in most environmental mycobacteria, including the *M. avium* complex<sup>25,26,27</sup>. The T cells that respond to the RD1 antigens are predominantly CD4. The phenotype of these cells can be characterized as being predominantly “effector memory” in patients with active disease (consistent with having recently encountered an antigen *in vivo*)<sup>28</sup> or as being predominantly, but not exclusively, “central memory” in those in whom Mtb replication is controlled either naturally (LTBI) or by drugs (patients successfully treated for active TB)<sup>28,29,30</sup>.

A particular advantage of *in vitro* testing is that stimulation reactions with negative and positive controls (mitogen stimulus) are carried out in parallel, primarily to evaluate test performance with respect to background signals or general T cell responsiveness. In the setting of immunodeficiency, an impaired mitogen response may additionally be interpreted as a meaningful measure for assessing the overall extent of immunosuppression. Therefore, unlike TST, *in vitro* tests may be able to discriminate true negative responses from anergy. In general, the results of IGRA and TST correspond poorly, although agreement is stronger in countries with a low TB prevalence and low BCG-vacci-

nation coverage<sup>31</sup>, as reported in detail below. Moreover, compared to the TST, positive IGRA responses are more closely associated with risk factors for LTBI.

### Accuracy of TST and IFN- $\gamma$ Release Assays in Immune Competent Subjects

IGRA have the same Achilles' heel as TST: there is no "gold standard" for LTBI. Therefore, as surrogate "standards," "active TB" status is used when assessing IGRA sensitivity, and subjects at extremely low risk when assessing specificity<sup>22,32</sup> (Table 1).

**Sensitivity.** Several metaanalyses report that the sensitivity of both IGRA in detecting active TB is higher (78–92%) than that of the TST (65–77%); however, the sensitivities of IGRA are not high enough to be used as tests to rule out active TB<sup>33</sup>.

**Specificity.** The specificity for the detection of active TB is higher for IGRA than for TST when considering BCG-vaccinated subjects among those without active disease. Indeed, Pai, *et al* reported a pooled specificity of 99% among non-BCG-vaccinated and 96% among BCG-vaccinated low-risk groups<sup>31</sup>. However, as shown recently<sup>33</sup> by a metaanalysis conducted by TBNET<sup>34</sup>, when assessed among controls including TB suspects, specificity decreased (59–79%) and thus must be considered as insufficient. These assays cannot, therefore, distinguish between active TB and LTBI, as also previously shown<sup>24,35,36</sup>.

**Negative predictive value.** Studies performed in low-incidence countries showed that the negative predictive value for progression to TB within 2 years is high (98–99% for IGRA), whereas it is lower in an intermediate-burden country such as Thailand (88%)<sup>37</sup>. In the few studies in which IGRA and the TST were concomitantly performed to compare the negative predictive value estimates, it was shown that the negative predictive value for the TST was 99.7% compared to 100% for the QFT-GIT<sup>37</sup>.

**Positive predictive value.** The strength of the association between positive IGRA results and development of active TB was reported as weak to moderate, with relative risks of about 2–3 when considering studies performed in high-prevalence, low- and middle-income settings; the analysis was done using in-house developed and commercial IGRA<sup>18</sup>. Differently, a metaanalysis of studies conducted on individuals from a low-prevalence setting using only commercial IGRA showed a relative risk varying between 8 and 15<sup>37</sup>. Recently an additional metaanalysis, involving only studies with a definite followup for the development of active TB, was performed. This analysis showed relative risks of up to 6.8 for IGRA and 2.4 for the TST<sup>38</sup>. Therefore up to now, no available tests for LTBI have been shown to have a high prognostic value. However, in some populations the proportion of IGRA-positive individuals might generally be lower than the proportion of

TST-positive individuals. This characteristic of IGRA might be useful in settings in which TST specificity is compromised by cross-reactivity with environmental mycobacteria, BCG-vaccination after infancy, or multiple BCG-vaccinations.

### Accuracy in Vulnerable Populations and Persons with Autoimmune Diseases

Patients with rheumatoid arthritis (RA) not undergoing immunosuppressive therapy are characterized by a reduced recall response, often called anergy, which leads to false-negative TST results<sup>39,40</sup>. This effect may be due to T cell abnormalities and to the reduced antigen presenting capacity of monocytes<sup>41,42</sup>; a decrease in memory CD4 T cells (CD4+CD45RA-) has also been found in anergic patients, which may also contribute to the decrease in antigen reactivity<sup>43</sup>. Immune-suppressive therapy may worsen this situation. In fact, it has been shown that high doses of prednisone ( $\geq 15$  mg/day)<sup>44</sup> and methotrexate, both drugs used for the treatment of RA, can cause false-negative TST reactions<sup>44</sup>. Similarly, *in vivo*, TNF antagonists have been shown to decrease the frequency of the subpopulation of memory CD4 T cells, rapidly releasing IFN- $\gamma$  upon challenge with mycobacterial antigens (PPD, CFP-10)<sup>45</sup>. Moreover, if TNF antagonists are added *in vitro*, they inhibit the activation of CD4 T cells by mycobacterial antigens<sup>45</sup>.

The literature contains evidence that in subjects with autoimmune diseases screened for LTBI, IGRA may provide a higher proportion of positive responses than TST<sup>46</sup>; indeed, up to 50% of IGRA-positive patients are missed by the TST<sup>47,48,49,50</sup>. This is probably because IGRA are *in vitro* tests relying on rapid production of IFN- $\gamma$  by circulating mononuclear cells in response to antigens, whereas the TST requires an intradermal infiltration of T-specific cells through the induction of several cytokines, including TNF, often reduced by drug administration. Moreover, the advantages of IGRA are that confounding factors related to BCG-vaccination are avoided, IGRA are closely associated with risk factors for LTBI<sup>50</sup>, and they have a low rate of indeterminate results (0–10.3%)<sup>47</sup>. Current evidence suggests that IGRA and TST results correspond poorly, although agreement is stronger in countries with a low prevalence of TB and low BCG-vaccination coverage<sup>47,51</sup>. Ideally in the clinical setting, immune-based diagnosis for LTBI is performed to identify individuals at risk of developing TB, but up to now, the positive predictive value of IGRA responses for development of TB in candidates undergoing therapy with TNF antagonists is not known. IGRA have shown to have a high negative predictive value for active TB development<sup>52,53,54</sup> in immunocompromised patients other than those with autoimmune diseases, such as HIV-infected subjects. Currently, among those with previous TB successfully treated, it is unknown whether the individuals with persistent positive IGRA scores have a higher risk of reactivating TB than subjects scored as

IGRA-negative or subjects who reverted from a positive to a negative IGRA. Moreover, it is still unclear whether IGRA testing may also be more accurate than TST for screening patients who have already received TNF antagonists, as results vary from one study to another<sup>47,48,49,50</sup>. The potential superiority of the IGRA over TST is reasonable; however, to prove it, we need studies that evaluate the positive predictive value of different immunodiagnostic tests in these patients.

### Serial IFN- $\gamma$ Assays

Serial testing for LTBI is performed every 1–2 years in highly exposed groups, such as healthcare workers and prisoners, as well as patients at high risk of disease, such as HIV-infected subjects or subjects with autoimmune diseases who are candidates for biologic agents. Although it has been reported that TST may boost IGRA responses, this effect is not seen if IGRA are done within 3 days of performing the TST<sup>6,55</sup>.

Unlike the TST, which should only be repeated if previously negative, IGRA tests may be repeated. However, high rates of spontaneous reversions and conversions are found in those untreated with anti-TB drugs, although it is always difficult to know whether conversion is spontaneous or a consequence of real Mtb infection or laboratory inaccuracy<sup>32,56</sup>.

Although QFT-GIT conversion has been reported to be related to higher risk of progression to TB<sup>57</sup>, especially in particular circumstances such as when children are exposed to Mtb as newborns<sup>58</sup>, or in patients with autoimmune diseases receiving biologic therapies<sup>59</sup>, the predictive value of IGRA (QFT-GIT) conversion for development of TB disease is still debated, and fluctuations in IFN- $\gamma$  responses among serially tested individuals reported in longitudinal studies remain unexplained and nonspecific.

Importantly, spontaneous reversions and conversions are more frequent in subjects with borderline results close to cutoff values and are more likely if scored negative in the TST<sup>51,60</sup>. In such cases, it has been interpreted as self-clearance of infection, but there is not enough evidence to draw such a conclusion<sup>56,61</sup>. For these reasons, serial testing with IGRA should be considered unreliable and is not recommended, at least until the conversion and reversion phenomena are better understood in both immune-suppressed and immune-competent patients<sup>32,51</sup>.

### Potential Improvement of Immune-based Tests

Potential improvement of immune-based tests can be achieved using different cutoff points and formats.

*Different cutoff points and the proposed concept of a “gray zone.”* Using the TST, subjects are classified as positive or negative for LTBI using cutoff points depending upon the presence or absence of key comorbidities, such as HIV, autoimmune diseases, as well as a given epidemiological situation.

As shown above, IGRA promises to be more specific than the TST. However, no “gold standard” for LTBI is available. In addition, the intensity of IFN- $\gamma$  responses may vary with the underlying condition, i.e., TB or LTBI: for a fixed cutoff point, sensitivity may be different if the IGRA is used to detect active TB as opposed to LTBI. It has recently been shown that test specificity for LTBI and test sensitivity for active TB actually depend upon the proportion of active TB and LTBI subjects in the study population and that there is a tradeoff between maximizing the specificity of IGRA to LTBI and sensitivity to active TB. Different cutoff points for IGRA use in suspected TB and suspected LTBI subjects in relationship to the prevalence of TB in that country will probably be needed<sup>62,63</sup>.

Moreover, during QFT-GIT serial testing, previous studies found nonspecific variations, defined as an “uncertainty zone” (IFN- $\gamma$  value in response to Mtb antigen between 0.20 and 0.50 IU/ml) and a “gray zone” (IFN- $\gamma$  value in response to Mtb antigen between 0.10 and 0.35 IU/ml)<sup>32,61,64</sup>. Recent studies on subjects with autoimmune diseases also considered the use of different cutoff values for LTBI diagnosis but did not reach any final conclusions<sup>51,65</sup>.

### Different Formats

Neither of the 2 IGRA can currently distinguish active TB from LTBI. Consequently, novel concepts that include the use of different antigens and readouts have been investigated to develop better assays.

*Antigens.* To design new diagnostics, it is necessary to extend our knowledge of potential immunogenic Mtb antigens<sup>66,67</sup>. Ideally, antigens should represent the different stages of Mtb infection and should include Mtb antigens expressed during the early onset of infection (growth stage), the latent/dormancy stage, and resuscitation of the dormancy stage<sup>68,69</sup>.

*Epitopes of CFP-10 and ESAT-6.* Different epitopes of CFP-10 and ESAT-6 selected by computational analysis to be multi-epitopic, called “RD1 selected peptides”<sup>24,70</sup>, have been shown to be associated with the active phase of Mtb replication as in active TB<sup>30,71,73</sup> and recent infection<sup>73</sup>. Unlike QFT-GIT, the RD1-selected peptide response decreases significantly after therapy for active disease<sup>74,75,76,77</sup> or prophylaxis in recent infections<sup>73</sup>. The difference might be related to the amount and composition of epitopes covered by the peptides used in the 2 different tests: QFT-GIT peptides cover all the CFP-10 and ESAT-6 intact proteins<sup>22</sup> (in addition to having TB7.7 peptide from the RD11 region) whereas the RD1-selected peptides are few and selected to be highly immunogenic<sup>24,70</sup>. Therefore, an oligoclonal response (rather than a polyclonal one against all RD1 epitopes) appears to be a sensitive tool for monitoring Mtb replication<sup>73</sup> as well as active disease<sup>74,75</sup>.

*Secreted antigens other than CFP-10 and ESAT-6.* Rv3615c encoded outside RD1, similar in size and sequence

homology to CFP-10 and ESAT-6, has been shown to be highly immunogenic and associated with Mtb-specific responses<sup>78</sup>.

*Antigens of latency.* During LTBI, persisting tubercle bacilli are deprived of nutrients and oxygen<sup>10,11,79,80</sup> and, as part of the adaptive response of Mtb to hypoxia, expression of the dormancy survival regulator (DosR) regulon is observed. The functions of most DosR-regulon encoded proteins, hereafter referred to as “latency antigens,” are unknown<sup>81,82</sup>. However, it has recently been shown that IFN- $\gamma$  responses to certain latency antigens are associated with LTBI in peripheral blood<sup>66,83,84,85</sup>, and not at the site of TB disease<sup>9,86</sup>.

Similarly, an IFN- $\gamma$  response to heparin-binding hemagglutinin has been associated with LTBI<sup>87,88,89</sup>, whereas a low response was found in patients with active TB, because of the suppressive capacity of the Treg cells in the periphery<sup>88</sup>.

### Immune Factors Other Than IFN- $\gamma$

Immune factors other than IFN- $\gamma$  have been proposed as alternative markers to detect Mtb-specific responses using the QFT-GIT. There is strong evidence that IFN- $\gamma$ -inducible protein-10 is an alternative marker of Mtb-specific responses<sup>71,90,91</sup> with less dependence on the CD4 T cell counts in HIV-infected subjects<sup>72,92</sup>. Simultaneous detection of IFN- $\gamma$  and interleukin-2 profiles of RD1-specific T cells using a modified QFT-GIT has enabled identification of subjects with TB, distinguishing LTBI from active TB<sup>93</sup>. Polyfunctional T lymphocytes, cells simultaneously producing a range of cytokines, have been associated with superior functional capacity and are correlated with TB control<sup>28,94,95,96,97,98</sup>; moreover, an effector memory phenotype has been associated with active disease whereas a central memory phenotype has been associated with cured TB or LTBI stages in HIV-uninfected<sup>28</sup> or HIV-infected subjects<sup>98</sup>.

TST measures *in vivo* PPD-specific cell-mediated immunity. Because of its poor specificity, this test may be inadequate to assess evidence of LTBI in BCG-vaccinated patients. IGRA are *in vitro* tests that rely on the rapid production of IFN- $\gamma$  by circulating mononuclear cells in response to Mtb-specific antigens. IGRA testing in vulnerable patients such as individuals with immune-mediated inflammatory diseases is feasible because of a strong correlation with risk factors for TB.

Longitudinal studies are needed to estimate the risk of progression to TB after IGRA-based and/or TST-based diagnosis of LTBI in these vulnerable patients. Serial IGRA testing is not recommended for those already scored positive. As previously established for TST, IGRA cutoff stratification based on age and immune suppression is probably needed. New immune-based tests are needed to distinguish active TB from LTBI and as tools that may help

to predict which subjects with LTBI will develop active TB, thereby improving the identification of subjects needing prophylaxis.

The above discussion on performance of assays can be summarized as follows:

- Among patients with autoimmune diseases, up to 50% of IGRA-positive patients are missed by TST, suggesting that IGRA are accurate tests for LTBI diagnosis in these patients
- Longitudinal studies are needed to estimate the risk of progression to TB after an IGRA/TST-based diagnosis of LTBI, because of the low estimated risk found in immune-competent subjects
- Owing to scarce evidence, it is safer to suggest both the TST and IGRA as screening tests for LTBI in patients with autoimmune diseases
- Based on the present evidence, serial tests are not recommended for IGRA-positive subjects.

### ACKNOWLEDGMENT

We are deeply grateful to Ms. Andrea Baker (INMI Rome, Italy) for English editing, and Dr. Elisa Petruccioli and Linda Petrone for their help editing the references.

### REFERENCES

1. Barry SM, Lipman MC, Bannister B, Johnson MA, Janosy G. Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. *J Infect Dis* 2003;187:243-50.
2. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. *Eur Respir J* 2009;33:956-73.
3. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2006;54:2368-76.
4. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. *Clin Infect Dis* 2004;39:1254-5.
5. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum* 2004;50:372-9.
6. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee MK. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. *Chest* 2008;133:1415-20.
7. Gibbs JH, Ferguson J, Brown RA, Kenicer KJ, Potts RC, Coghil G, et al. Histometric study of the localisation of lymphocyte subsets and accessory cells in human Mantoux reactions. *J Clin Pathol* 1984;37:1227-34.
8. Platt JL, Grant BW, Eddy AA, Michael AF. Immune cell populations in cutaneous delayed-type hypersensitivity. *J Exp Med* 1983;158:1227-42.
9. Place S, Verscheure V, de San N, Hougardy JM, Schepers K, Dirix V, et al. Heparin-binding, hemagglutinin-specific IFN-gamma

- synthesis at the site of infection during active tuberculosis in humans. *Am J Respir Crit Care Med* 2010;182:848-54.
10. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. *Lancet Infect Dis* 2003;3:578-90.
  11. Tufariello JM, Jacobs WR Jr, Chan J. Individual Mycobacterium tuberculosis resuscitation-promoting factor homologues are dispensable for growth in vitro and in vivo. *Infect Immun* 2004;72:515-26.
  12. Sarrazin H, Wilkinson KA, Andersson J, Rangaka MX, Radler L, van Veen K, et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. *J Infect Dis* 2009;199:702-10.
  13. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, Selin MJ, Good RC, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. *Am Rev Respir Dis* 1992;145:1160-6.
  14. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? *Int J Tuberc Lung Dis* 2006;10:1192-204.
  15. Diel R, Ernst M, Doscher G, Visuri-Karbe L, Greinert U, Niemann S, et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. *Eur Respir J* 2006;28:16-23.
  16. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. *AIDS* 1999;13:501-7.
  17. Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. *Pulm Med* 2013;2013:601737.
  18. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis* 2012;12:45-55.
  19. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. *Clin Infect Dis* 2007;44:94-102.
  20. Martin-Echevarria E, Rodriguez-Zapata M, Torralba M, Fernandez JM, Moreno A, Casado JL, et al. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count. *Int J Tuberc Lung Dis* 2011;15:1347-52.
  21. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. *PLoS One* 2012;7:e32482.
  22. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. *Am J Respir Crit Care Med* 2004;170:59-64.
  23. Whitworth HS, Scott M, Connell DW, Donges B, Lalvani A. IGRAs — The gateway to T cell based TB diagnosis. *Methods* 2013;61:52-62.
  24. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. *Clin Diagn Lab Immunol* 2005;12:1311-6.
  25. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. *Lancet* 2000;356:1099-104.
  26. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. *J Bacteriol* 1996;178:1274-82.
  27. Gey van Pittius NC, Sampson SL, Lee H, Kim Y, van Helden PD, Warren RM. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. *BMC Evol Biol* 2006;6:95.
  28. Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, et al. IFN-gamma/TNF-alpha specific-cells and effector memory phenotype associate with active tuberculosis. *J Infect* 2013;66:475-86.
  29. Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. *J Immunol* 2007;178:5217-26.
  30. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, Poccia F. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. *J Infect Dis* 2006;194:984-92.
  31. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med* 2008;149:177-84.
  32. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. *Int J Tuberc Lung Dis* 2009;13:84-92.
  33. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2011;37:100-11.
  34. Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo D, et al. TBNET – Collaborative research on tuberculosis in Europe. *Eur J Microbiol Immunol* 2012;2:264-74.
  35. Goletti D, Carrara S, Vincenti D, Saltini C, Rizzi EB, Schinina V, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. *Clin Microbiol Infect* 2006;12:544-50.
  36. Goletti D, Carrara S, Butera O, Amicosante M, Ernst M, Sauzullo I, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. *PLoS One* 2008;3:e3417.
  37. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. *Eur Respir J* 2011;37:88-99.
  38. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. *Chest* 2012;142:63-75.
  39. Sezer I, Kocabas H, Melikoglu MA, Arman M. Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. *Clin Rheumatol* 2009;28:53-7.
  40. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. *Ann Rheum Dis* 2005;64:1360-1.
  41. Seitz M, Napierski I, Kirchner H. Depressed PPD and tetanus toxoid presentation by monocytes to T lymphocytes in patients with rheumatoid arthritis: restoration by interferon gamma. *Rheumatol Int* 1988;8:189-96.
  42. Halloran PF. Immunosuppressive drugs for kidney transplantation. *N Engl J Med* 2004;351:2715-29.
  43. Verwilghen J, Vertessen S, Stevens EA, Dequeker J, Ceuppens JL.

- Depressed T-cell reactivity to recall antigens in rheumatoid arthritis. *J Clin Immunol* 1990;10:90-8.
44. Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. *Inflamm Bowel Dis* 2011;17:2340-9.
  45. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. *Arthritis Res Ther* 2006;8:R114.
  46. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. *J Rheumatol* 2008;35:776-81.
  47. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. *Eur Respir J* 2009;33:586-93.
  48. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. *Eur J Clin Microbiol Infect Dis* 2008;27:907-13.
  49. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. *Ann Rheum Dis* 2010;69:181-5.
  50. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. *Ann Rheum Dis* 2008;67:84-90.
  51. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, et al. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. *J Infect* 2013;66:346-56.
  52. Aichelburg MC, Rieger A, Breitenacker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. *Clin Infect Dis* 2009;48:954-62.
  53. Clark SA, Martin SL, Pozniak A, Steel A, Ward B, Dunning J, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. *Clin Exp Immunol* 2007;150:238-44.
  54. Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-gamma release assay, and the development of active tuberculosis in HIV-seropositive persons. *Diagn Microbiol Infect Dis* 2011;69:59-65.
  55. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. *Am J Respir Crit Care Med* 2009;180:49-58.
  56. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. *Am J Respir Crit Care Med* 2006;174:831-9.
  57. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. *Am J Respir Crit Care Med* 2012;186:1051-6.
  58. Richeldi L, Ewer K, Losi M, Bergamini BM, Millington K, Fabbri LM, et al. T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. *Pediatrics* 2007;119:e1-5.
  59. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. *Ann Rheum Dis* 2012;71:231-7.
  60. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB gold in-tube assay. *Clin Vaccine Immunol* 2008;15:425-32.
  61. Harada N, Mori T, Shishido S, Higuchi K, Sekiya Y. Usefulness of a novel diagnostic method of tuberculosis infection, QuantiFERON TB-2G, in an outbreak of tuberculosis. *Kekkaku* 2004;79:637-43.
  62. Davidow AL, Affouf M. Making sense of agreement among interferon-gamma release assays and tuberculosis skin testing. *Int J Tuberc Lung Dis* 2008;12:152-9.
  63. Vesenbeckh SM, Schonfeld N, Mauch H, Bergmann T, Wagner S, Bauer TT, et al. The use of interferon gamma release assays in the diagnosis of active tuberculosis. *Tuberc Res Treat* 2012;2012:768723.
  64. Harada N, Higuchi K, Sekiya Y, Rothel J, Kitoh T, Mori T. Basic characteristics of a novel diagnostic method (QuantiFERON TB-2G) for latent tuberculosis infection with the use of Mycobacterium tuberculosis-specific antigens, ESAT-6 and CFP-10. *Kekkaku* 2004;79:725-35.
  65. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. *Ann Rheum Dis* 2012;71:231-7.
  66. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. *Clin Vaccine Immunol* 2009;16:1203-12.
  67. Ottenhoff TH. The knowns and unknowns of the immunopathogenesis of tuberculosis. *Int J Tuberc Lung Dis* 2012;16:1424-32.
  68. Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL, Drijfhout JW, et al. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. *Eur J Immunol* 2011;41:2925-36.
  69. Commandeur S, van Meijgaarden KE, Lin MY, Franken KL, Friggen AH, Drijfhout JW, et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. *Clin Vaccine Immunol* 2011;18:676-83.
  70. Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, Palmieri F, et al. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. *Mol Med* 2003;9:105-11.
  71. Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. *J Infect* 2010;61:133-43.
  72. Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, Carrara S, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? *PLoS One* 2010;5:e12577.
  73. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. *Respir Res* 2007;8:5.
  74. Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. *Clin Infect Dis* 2004;38:754-6.
  75. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA,

- Girardi E, et al. Response to *M. tuberculosis* selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. *BMC Infect Dis* 2008;8:11.
76. Kabeer BS, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. *BMC Infect Dis* 2011;11:135.
  77. Latorre I, Altet N, de Souza-Galvao M, Ruiz-Manzano J, Lacoma A, Prat C, et al. Specific *Mycobacterium tuberculosis* T cell responses to RD1-selected peptides for the monitoring of anti-tuberculosis therapy. *Scand J Infect Dis* 2012;44:161-7.
  78. Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, Wickremasinghe M, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for *Mycobacterium tuberculosis* infection. *Proc Natl Acad Sci U S A* 2011;108:5730-5.
  79. Wayne LG. In vitro model of hypoxically induced nonreplicating persistence of *Mycobacterium tuberculosis*. *Methods Mol Med* 2001;54:247-69.
  80. Wayne LG, Hayes LG. Nitrate reduction as a marker for hypoxic shift-down of *Mycobacterium tuberculosis*. *Tuber Lung Dis* 1998;79:127-32.
  81. Yuan Y, Crane DD, Barry CE 3rd. Stationary phase-associated protein expression in *Mycobacterium tuberculosis*: function of the mycobacterial alpha-crystallin homolog. *J Bacteriol* 1996;178:4484-92.
  82. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of *Mycobacterium tuberculosis*. *Mol Microbiol* 2003;48:833-43.
  83. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. *Eur Respir J* 2010;36:135-42.
  84. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of *Mycobacterium tuberculosis*. *Microbes Infect* 2006;8:2052-60.
  85. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KL, et al. Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. *PLoS One* 2009;4:e5590.
  86. Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, et al. Higher frequency of T-cell response to *M. tuberculosis* latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. *PLoS One* 2011;6:e27539.
  87. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua A, et al. Methylated HBHA produced in *M. smegmatis* discriminates between active and non-active tuberculosis disease among RD1-responders. *PLoS One* 2011;6:e18315.
  88. Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, Loch C, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. *Am J Respir Crit Care Med* 2007;176:409-16.
  89. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verschueren V, et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. *PLoS One* 2007;2:e926.
  90. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. *Eur Respir J* 2008;32:1607-15.
  91. Ruhwald M, Petersen J, Kofoed K, Nakaoka H, Cuevas LE, Lawson L, et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. *PLoS One* 2008;3:e2858.
  92. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. *J Infect* 2012;65:49-59.
  93. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, et al. Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. *Clin Microbiol Infect* 2010;16:1282-4.
  94. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O'rie T, et al. Functional capacity of *Mycobacterium tuberculosis*-specific T cell responses in humans is associated with mycobacterial load. *J Immunol* 2011;187:2222-32.
  95. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, et al. Dominant TNF-alpha+ *Mycobacterium tuberculosis*-specific CD4+ T cell responses discriminate between latent infection and active disease. *Nat Med* 2011;17:372-6.
  96. Sester U, Fousse M, Dirks J, Mack U, Prasse A, Singh M, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. *PLoS One* 2011;6:e17813.
  97. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, et al. *Mycobacterium tuberculosis*-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease. *Eur J Immunol* 2013;43:1568-77.
  98. Schuetz A, Haule A, Reither K, Ngwenyama N, Rachow A, Meyerhans A, et al. Monitoring CD27 expression to evaluate *Mycobacterium tuberculosis* activity in HIV-1 infected individuals in vivo. *PLoS One* 2011;6:e27284.